(Figures in the brackets refer to the same period the previous year)
During the third quarter of 2023, BioGaia's sales have been impacted by increased demand in EMEA, the
For the third quarter, sales are preliminarily estimated at
BioGaia publishes the interim report for the third quarter 2023 on
Follow us:
Subscribe to BioGaia press releases here
LinkedIn here
Contacts:
Email: alexander.kotsinas@biogaia.com
Phone: +46 735 00 11 11
Email: mikaela.idermark.stern@biogaia.com
Phone: +46 730 95 61 50
About
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through distribution partners or through our own distribution in more than 100 countries worldwide. The class B share of the
This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact persons set out above, at
https://news.cision.com/biogaia/r/biogaia-s-results-for-the-third-quarter-to-exceed-market-expectations,c3854782
https://mb.cision.com/Main/3271/3854782/2362522.pdf
(c) 2023 Cision. All rights reserved., source